When bullous pemphigoid presents with rapid, widespread blister formation across multiple body regions, it meets the threshold for severe disease. This clinical scenario — defined by both a quantifiable blister count and a validated severity score — calls for a structured, evidence-based first-line approach to bring active disease under control.
Bullous pemphigoid with 10 or more new blisters daily on multiple anatomical sites, and/or a BPDAI (Bullous Pemphigoid Disease Area Index) score of 57 or more — classified as severe disease.
Two distinct first-line options are available for this severe presentation: one centred on a high-potency topical corticosteroid and the other on systemic oral corticosteroid therapy. Selection between them depends on patient-specific factors.
Complete regimen details, dosing guidance, and the full decision algorithm are in the structured protocol below ↓
The primary aim is control of disease activity — defined as the point at which new lesions and pruritic symptoms cease to form and established lesions begin to heal. In severe bullous pemphigoid, achieving this control by day 21 is substantially harder than in milder presentations, reached in only 46% of severe patients with one of the standard starting regimens.